Entry into a Material Definitive Agreement

On November 21, 2022, Thermo Fisher Scientific Inc. (the "Company") reported that issued €500,000,000 aggregate principal amount of 3.200% Senior Notes due 2026 (the "2026 Notes") and €750,000,000 aggregate principal amount of 3.650% Senior Notes due 2034 (the "2034 Notes", and, together with the 2026 Notes, the "Euro Notes") in a public offering (the "Euro Offering") pursuant to a registration statement on Form S-3 (File No. 333-263034) and a preliminary prospectus supplement and prospectus supplement related to the offering of the Euro Notes, each as previously filed with the Securities and Exchange Commission (the "SEC") (Filing, 8-K, Thermo Fisher Scientific, NOV 21, 2022, View Source [SID1234624282]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Euro Notes were issued under an indenture, dated as of November 20, 2009 (the "Base Indenture"), and the Twenty-Fifth Supplemental Indenture, dated as of November 21, 2022 (the "Euro Supplemental Indenture" and, together with the Base Indenture, the "Euro Indenture"), between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee (the "Trustee").

The 2026 Notes will mature on January 21, 2026 and the 2034 Notes will mature on November 21, 2034. Interest on the 2026 Notes will be paid annually in arrears on January 21 of each year, commencing on January 21, 2023, and interest on the 2034 Notes will be paid annually in arrears on November 21 of each year, commencing on November 21, 2023.

Prior to December 21, 2025, in the case of the 2026 Notes, and August 21, 2034, in the case of the 2034 Notes (each such date, a "Euro Par Call Date"), the Company may redeem either series of Euro Notes, in whole at any time or in part from time to time, at a redemption price equal to the greater of (1) 100% of the principal amount of the Euro Notes to be redeemed and (2) the sum of the present values of the remaining scheduled payments of principal and interest in respect of the Euro Notes being redeemed (not including any portion of the payments of interest accrued but unpaid as of the date of redemption and assuming that such notes to be redeemed matured on their applicable Euro Par Call Date), discounted to the date of redemption on an annual basis (ACTUAL/ACTUAL (ICMA)), using a discount rate equal to the Comparable Bond Rate (as defined in the Euro Indenture) plus 20 basis points, in the case of the 2026 Notes, and 25 basis points, in the case of the 2034 Notes, plus, in each case, accrued and unpaid interest on the Euro Notes being redeemed, if any, to, but excluding, the date of redemption.

In addition, on and after the applicable Euro Par Call Date, the Company may redeem some or all of the Euro Notes at a redemption price equal to 100% of the principal amount of the Euro Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding the date of redemption.

Upon the occurrence of a change of control (as defined in the Euro Indenture) of the Company and a contemporaneous downgrade of the Euro Notes below an investment grade rating by at least two of Moody’s Investors Service, Inc., S&P Global Ratings, a division of S&P Global, Inc., and Fitch Ratings, Limited, the Company will, in certain circumstances, be required to make an offer to purchase the Euro Notes at a price equal to 101% of the principal amount of the Euro Notes, plus any accrued and unpaid interest to, but excluding, the date of repurchase.

The Euro Notes are general unsecured obligations of the Company. The Euro Notes rank equally in right of payment with existing and any future unsecured and unsubordinated indebtedness of the Company and rank senior in right of payment to any existing and future indebtedness of the Company that is subordinated to the Euro Notes. The Euro Notes are also effectively subordinated to any existing and future secured indebtedness of the Company to the extent of the assets securing such indebtedness, and are structurally subordinated to all existing and any future indebtedness and any other liabilities of its subsidiaries.
The Euro Indenture contains limited affirmative and negative covenants. The negative covenants restrict the ability of the Company and its subsidiaries to incur debt secured by liens on Principal Properties (as defined in the Euro Indenture) or on shares of stock of the Company’s Principal Subsidiaries (as defined in the Euro Indenture) and engage in sale and lease-back transactions with respect to any Principal Property. The Euro Indenture also limits the ability of the Company to merge or consolidate or sell all or substantially all of its assets.

Upon the occurrence of an event of default under the Euro Indenture, which includes payment defaults, defaults in the performance of affirmative and negative covenants, bankruptcy and insolvency related defaults and failure to pay certain indebtedness, the obligations of the Company under the Euro Notes may be accelerated, in which case the entire principal amount of the Euro Notes would be immediately due and payable.

Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Company, has issued an opinion to the Company, dated November 21, 2022, regarding the Euro Notes. A copy of this opinion is filed as Exhibit 5.1 hereto.

The foregoing description is qualified in its entirety by reference to the full text of the Base Indenture and the Euro Supplemental Indenture, which are filed with this report as Exhibits 4.1 and 4.2 hereto, respectively. Each of the foregoing documents is incorporated herein by reference.

USD Offering

On November 21, 2022, the Company issued $600,000,000 aggregate principal amount of 4.800% Senior Notes due 2027 (the "2027 Notes") and $600,000,000 aggregate principal amount of 4.950% Senior Notes due 2032 (the "2032 Notes" and, together with the 2027 Notes, the "USD Notes") in a public offering (the "USD Offering") pursuant to a registration statement on Form S-3 (File No. 333-263034) and a preliminary prospectus supplement and prospectus supplement related to the offering of the USD Notes, each as previously filed with the SEC.

The USD Notes were issued under the Base Indenture and the Twenty-Sixth Supplemental Indenture, dated as of November 21, 2022 (the "USD Supplemental Indenture" and, together with the Base Indenture, the "USD Indenture"), between the Company and the Trustee.

The 2027 Notes will mature on November 21, 2027, and the 2032 Notes will mature on November 21, 2032. Interest on the USD Notes will be paid semi-annually in arrears on May 21 and November 21 of each year, commencing on May 21, 2023.

Prior to October 21, 2027, in the case of the 2027 Notes, and August 21, 2032, in the case of the 2032 Notes (each, a "USD Par Call Date"), the Company may redeem either series of USD Notes, in whole at any time or in part from time to time, at a redemption price equal to the greater of (1) 100% of the principal amount of the USD Notes of such series to be redeemed and (2) the sum of the present values of the remaining scheduled payments of principal and interest in respect of the USD Notes of such series being redeemed (not including any portion of the payments of interest accrued but unpaid as of the date of redemption and assuming that such USD Notes to be redeemed matured on their applicable USD Par Call Date), discounted to the date of redemption on a semi-annual basis (assuming a 360-day year of twelve 30-day months), at the Treasury Rate (as defined in the USD Indenture) plus 15 basis points, in the case of the 2027 Notes, and 20 basis points, in the case of the 2032 Notes, plus, in each case, accrued and unpaid interest on the USD Notes of such series being redeemed, if any, to, but excluding, the date of redemption.
In addition, on and after the applicable USD Par Call Date, the Company may redeem some or all of the USD Notes at a redemption price equal to 100% of the principal amount of the USD Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding the date of redemption.

Upon the occurrence of a change of control (as defined in the USD Indenture) of the Company and a contemporaneous downgrade of the USD Notes below an investment grade rating by at least two of Moody’s Investors Service, Inc., S&P Global Ratings, a division of S&P Global, Inc., and Fitch Ratings, Limited, the Company will, in certain circumstances, be required to make an offer to purchase the USD Notes at a price equal to 101% of the principal amount of the USD Notes, plus any accrued and unpaid interest to, but excluding, the date of repurchase.

The USD Notes are general unsecured obligations of the Company. The USD Notes rank equally in right of payment with existing and any future unsecured and unsubordinated indebtedness of the Company and rank senior in right of payment to any existing and future indebtedness of the Company that is subordinated to the USD Notes. The USD Notes are also effectively subordinated to any existing and future secured indebtedness of the Company to the extent of the assets securing such indebtedness, and are structurally subordinated to all existing and any future indebtedness and any other liabilities of its subsidiaries.

The USD Indenture contains limited affirmative and negative covenants. The negative covenants restrict the ability of the Company and its subsidiaries to incur debt secured by liens on Principal Properties (as defined in the USD Indenture) or on shares of stock of the Company’s Principal Subsidiaries (as defined in the USD Indenture) and engage in sale and lease-back transactions with respect to any Principal Property. The USD Indenture also limits the ability of the Company to merge or consolidate or sell all or substantially all of its assets.

Upon the occurrence of an event of default under the USD Indenture, which includes payment defaults, defaults in the performance of affirmative and negative covenants, bankruptcy and insolvency related defaults and failure to pay certain indebtedness, the obligations of the Company under the USD Notes may be accelerated, in which case the entire principal amount of the USD Notes would be immediately due and payable.

Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Company, has issued an opinion to the Company, dated November 21, 2022, regarding the USD Notes. A copy of this opinion is filed as Exhibit 5.2 hereto.

The foregoing description is qualified in its entirety by reference to the full text of the Base Indenture and the USD Supplemental Indenture, which are filed with this report as Exhibits 4.1 and 4.3 hereto, respectively. Each of the foregoing documents is incorporated herein by reference.

AskGene Announces Submission of IND to FDA for ASKG915

On November 21, 2022 AskGene Pharma Inc. reported the submission of an Investigational New Drug (IND) application for ASKG915 to the United States Food and Drug Administration (FDA) (Press release, AskGene Pharmaceuticals, NOV 21, 2022, View Source [SID1234624281]). ASKG915 is a recombinant human anti-PD-1 monoclonal antibody and IL-15 prodrug fusion protein for oncology indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jian-Feng (Jeff) Lu, Ph.D., CEO of AskGene commented: "ASKG915 is our third cytokine prodrug entering clinical development, which was discovered and developed using our propriety SmartKine cytokine platform technology. Based on the projected dose, it will have full bifunction activities encompassing the combined therapeutic potencies of IL-15 super-agonist and Anti-PD1. ASKG915 is the first anti-PD-1-IL-15 prodrug fusion molecule moving into clinical development. It represents the next generation of immunotherapy and is expected to achieve better safety, efficacy, and overall benefit for patients, especially those who may not respond to current immunotherapies."

PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy Congress

On November 21, 2022 PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, reported two executives will be giving presentations at the World Vaccine & Immunotherapy Congress, which will take place from November 28 through December 1, 2022, in San Diego (Press release, PDS Biotechnology, NOV 21, 2022, View Source [SID1234624280]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Development of a universal flu vaccine based on the InfectimuneTM platform

More than 800 attendees are expected to attend the World Vaccine & Immunotherapy Congress to examine challenges around scientific, commercial, public health and policy issues in manufacturing, clinical trials, regulation, immune profiling, biomarkers, platform technologies, and additional topics.

"We welcome the opportunity to highlight the Versamune and Infectimune platforms and their potential to address significant unmet medical needs to the biotechnology and scientific community," said Dr. Frank Bedu-Addo, PDS Biotech President and CEO. "We are looking forward to advancing our product development in both oncology and infectious disease, ultimately to improve patient care."

About Versamune

Current immunotherapies have demonstrated an ability to treat certain cancers, but limitations with their effectiveness persist. Versamune is a novel investigational T cell activating platform designed to stimulate a precise immune system response to cancer-specific proteins. PDS Biotech is advancing multiple Versamune based clinical and pre-clinical programs with its lead clinical candidate – PDS0101 – targeting HPV-positive cancers.

About InfectimuneTM

Infectimune is a novel proprietary investigational T cell immune activating platform technology designed to train the immune system to better protect against disease. The Infectimune platform stimulates the immune system to recognize the pathogen and induce potent killer T cell and memory T cell response for long-term protection safely with no clinically relevant toxicities.

Heron Therapeutics Announces Virtual Presentation at Evercore ISI 5th Annual HealthCONx Conference

On November 21, 2022 Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, reported that company management will participate in a fireside chat on Thursday, December 1, 2022 at 10:05 AM ET at the Evercore ISI 5th Annual HealthCONX Conference (Press release, Heron Therapeutics, NOV 21, 2022, View Source [SID1234624279]). The conference is being held in a virtual format, November 29-December 1, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the Company’s website at www.herontx.com in the Investor Resources section.

UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference

On November 21, 2022 UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, reported that it will participate in a virtual fireside chat at the upcoming Evercore ISI 5th Annual HealthCONx Conference on November 29, 2022 at 3:55 PM ET (Press release, UroGen Pharma, NOV 21, 2022, https://investors.urogen.com/news-releases/news-release-details/urogen-pharma-present-evercore-isi-5th-annual-virtual-healthconx [SID1234624278]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available in the "Events and Presentations" section of UroGen’s investor website. A replay will be available for approximately 30 days.